Evidence map›Paper›PMID 34555850›Full record

ArticleBlood advances2022

Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors.

Jingyu Xiang, Min Shi, Mark A Fiala, Feng Gao, Michael P Rettig, Geoffrey L Uy, Mark A Schroeder, Katherine N Weilbaecher, Keith E Stockerl-Goldstein, Shamim Mollah and 1 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Machine Learning in Stem Cell Research: From Biological Data to Clinical Translation.Computational and structural biotechnology journal · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Deep Learning in Hematology: From Molecules to Patients.Clinical hematology international · 2024
    Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Jingyu XiangDivision of Oncology, Department of Medicine.
Min ShiDepartment of Genetics.ORCID 0000-0003-4017-5377
Mark A FialaDivision of Oncology, Department of Medicine.
Feng GaoDivision of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO.
Michael P RettigDivision of Oncology, Department of Medicine.
Geoffrey L UyDivision of Oncology, Department of Medicine.ORCID 0000-0002-7809-0996
Mark A SchroederDivision of Oncology, Department of Medicine.ORCID 0000-0003-4924-8990
Katherine N WeilbaecherDivision of Oncology, Department of Medicine.ORCID 0000-0002-7137-4742
Keith E Stockerl-GoldsteinDivision of Oncology, Department of Medicine.
Shamim MollahDepartment of Genetics.ORCID 0000-0001-9178-8339
John F DiPersioDivision of Oncology, Department of Medicine.
Institute for Medical Informatics and Biostatistics · CHWashington University in St. Louis · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI TODD A FEHNIGER · 2013 to 2026
$31.6M
Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological MalignanciesR35CA210084 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio · 2017 to 2026
$7.8M
BM NICHE DISRUPTION AND IMMUNOTHERAPY IN HEMATOLOGICAL MALIGNANCIESR50CA211466 · NCI · WASHINGTON UNIVERSITY · PI Michael Rettig · 2016 to 2026
$2.3M
NCI NIH HHS P30 CA091842NCI NIH HHS P50 CA171963NCI NIH HHS R35 CA210084NCI NIH HHS R50 CA211466
6 · The paper itself

Abstract

Mobilized peripheral blood has become the primary source of hematopoietic stem cells for both autologous and allogeneic stem cell transplantation. Granulocyte colony-stimulating factor (G-CSF) is currently the standard agent used in the allogeneic setting. Despite the high mobilization efficacy in most donors, G-CSF requires 4-5 days of daily administration, and a small percentage of the donors fail to mobilize an optimal number of stem cells necessary for a safe allogeneic stem cell transplant. In this study, we retrospectively reviewed 1361 related allogeneic donors who underwent stem cell mobilization at Washington University. We compared the standard mobilization agent G-CSF with five alternative mobilization regimens, including GM-CSF, G-CSF+GM-CSF, GM-CSF + Plerixafor, Plerixafor and BL-8040. Cytokine-based mobilization strategies (G-CSF or in combination with GM-CSF) induce higher CD34 cell yield after 4-5 consecutive days of treatment, while CXCR4 antagonists (plerixafor and BL-8040) induce significantly less but rapid mobilization on the same day. Next, using a large dataset containing the demographic and baseline laboratory data from G-CSF-mobilized donors, we established machine learning (ML)-based scoring models that can be used to predict patients who may have less than optimal stem cell yields after a single leukapheresis session. To our knowledge, this is the first prediction model at the early donor screening stage, which may help identify allogeneic stem cell donors who may benefit from alternative approaches to enhance stem cell yields, thus ensuring safe and effective stem cell transplantation.

Indexed as

Hematopoietic Stem Cell TransplantationHeterocyclic CompoundsAntigens, CD34Granulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansMachine LearningRetrospective StudiesAntigens, CD34Granulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorHeterocyclic Compounds

Identifiers

PMID34555850
PMCPMC9006268
OpenAlexW3199706728

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.